RIMADYL 25 Tablet

Država: Južnoafrička Republika

Jezik: engleski

Izvor: South African Health Products Regulatory Authority (SAHPRA)

Dostupno od:

Zoetis South Africa (Pty) Ltd

Farmaceutski oblik:

Tablet

Sastav:

Each Tablet contains CARPROFEN 25.0 mg

Područje terapije:

C. 3.1.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs). Selective COX2 inhibitors.

Datum autorizacije:

2001-12-01

Svojstava lijeka

1
RIMADYL
® CHEWABLE 25
RIMADYL
® CHEWABLE 75
RIMADYL
® CHEWABLE 100
Chewable Tablets
VETERINARY MEDICINE
SCHEDULING STATUS:
Schedule 3
PROPRIETARY NAMES (AND DOSAGE FORMS):
RIMADYL CHEWABLE 25 chewable tablets
RIMADYL CHEWABLE 75 chewable tablets
RIMADYL CHEWABLE 100 chewable tablets
COMPOSITION:
RIMADYL CHEWABLE 25: Each tablet contains 25 mg Carprofen
RIMADYL CHEWABLE 75: Each tablet contains 75 mg Carprofen
RIMADYL CHEWABLE 100: Each tablet contains 100 mg Carprofen
PHARMACOLOGICAL CLASSIFICATION:
C 3.1.2.2 NSAIDs, Selective COX2 inhibitors
PHARMACOLOGICAL ACTION:
Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent
with characteristic analgesic and
antipyretic activity.
The
exact
mode
of
action
of
carprofen
has
not
been
established;
however,
inhibition
of
prostaglandin synthesis accounts for at least part of its mechanism of
action. Carprofen is a
moderately potent inhibitor of phospholipase A
2
and a reversible inhibitor of cyclo-oxygenase
(COX). In _ in-vitro _ cell-culture of canine origin, carprofen
displayed selectivity for COX-2, the
inducible form of the enzyme upregulated in damaged and inflamed
tissue, compared with its
inhibition of COX-1, the iso-enzyme which is involved in normal
gastric function.
Carprofen has also been shown to inhibit the release of prostaglandins
in acute polymorphonuclear
leukocytes and chronic inflammatory reactions.
2
Carprofen has modulatory effects on both humoral and cellular immune
responses. It inhibits the
production of osteoclast-activating factor (OAF), PGE
1
and PGE
2
by its inhibitory effects on
prostaglandin biosynthesis.
Following repeat therapeutic dosing for eight weeks, carprofen has
shown to have no
detrimental effect on canine arthritic cartilage. In addition,
therapeutic concentrations of
carprofen have been shown _ in-vitro _ to increase glycosaminoglycan
(GAG) synthesis in
chondrocytes derived
from
canine arthritic cartilage
.
Stimulation of GAG synthesis will narrow the difference between the
rate of degeneration and
regeneration of ca